{"id":"oral-capecitabine-with-irinotecan","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Diarrhea"},{"rate":"30-40","effect":"Neutropenia"},{"rate":"30-40","effect":"Nausea/vomiting"},{"rate":"30-40","effect":"Fatigue"},{"rate":"15-25","effect":"Hand-foot syndrome"},{"rate":"20-30","effect":"Anemia"},{"rate":"10-20","effect":"Mucositis"},{"rate":"15-25","effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL3989514","moleculeType":"Small molecule","molecularWeight":"677.19"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Capecitabine is an oral prodrug that undergoes hepatic and tumor-selective conversion to 5-fluorouracil (5-FU), which inhibits thymidylate synthase and incorporates into DNA/RNA to disrupt nucleotide synthesis. Irinotecan is a topoisomerase I inhibitor that prevents religation of DNA strands, leading to double-strand breaks during replication. The combination leverages complementary mechanisms of action to enhance cytotoxicity in rapidly dividing cancer cells.","oneSentence":"Capecitabine is converted to 5-fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, while irinotecan inhibits topoisomerase I to prevent DNA unwinding during replication, together producing synergistic cytotoxic effects against cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:24:41.927Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"},{"name":"Metastatic gastric cancer"},{"name":"Metastatic breast cancer"}]},"trialDetails":[{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT07024615","phase":"PHASE1","title":"A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-10-16","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":25},{"nctId":"NCT05365581","phase":"PHASE1","title":"A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2022-06-07","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma","enrollment":398},{"nctId":"NCT07395063","phase":"PHASE2","title":"A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond.","status":"NOT_YET_RECRUITING","sponsor":"The Fourth Affiliated Hospital of Zhejiang University School of Medicine","startDate":"2026-02-01","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":68},{"nctId":"NCT05412082","phase":"PHASE1","title":"SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"University of Miami","startDate":"2022-10-05","conditions":"Locally Advanced Rectal Cancer","enrollment":25},{"nctId":"NCT04749108","phase":"PHASE2, PHASE3","title":"Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma","status":"RECRUITING","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2021-11-26","conditions":"Locally Advanced Malignant Neoplasm, Rectal Carcinoma","enrollment":1075},{"nctId":"NCT05062889","phase":"PHASE2","title":"Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients","status":"SUSPENDED","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-17","conditions":"Stage II Colon Cancer, Stage III Colon Cancer, HER2-positive Colon Cancer","enrollment":477},{"nctId":"NCT04539808","phase":"PHASE2","title":"NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2021-05-27","conditions":"Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer American Joint Committee on Cancer v8, Stage I Pancreatic Cancer American Joint Committee on Cancer v8","enrollment":42},{"nctId":"NCT07056777","phase":"PHASE1, PHASE2","title":"Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With Standard Therapy in Patients With Gastrointestinal Cancer","status":"RECRUITING","sponsor":"Zhejiang Doer Biologics Co., Ltd.","startDate":"2025-03-25","conditions":"Gastrointestinal Cancer","enrollment":186},{"nctId":"NCT06741644","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"CStone Pharmaceuticals","startDate":"2025-02-24","conditions":"Advanced Solid Tumors","enrollment":660},{"nctId":"NCT07328919","phase":"PHASE3","title":"Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations","status":"NOT_YET_RECRUITING","sponsor":"TransThera Sciences (Nanjing), Inc.","startDate":"2026-01","conditions":"Intrahepatic Cholangiocarcinoma (Icc), Advanced Cholangiocarcinoma","enrollment":138},{"nctId":"NCT07229846","phase":"PHASE2","title":"A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation","status":"NOT_YET_RECRUITING","sponsor":"Yanqiao Zhang","startDate":"2026-02","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT06065371","phase":"PHASE1","title":"Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy","status":"RECRUITING","sponsor":"Henry Ford Health System","startDate":"2024-11-20","conditions":"Gastrointestinal Cancer","enrollment":20},{"nctId":"NCT07213570","phase":"PHASE2","title":"STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2025-10-16","conditions":"Colorectal Cancer Metastatic","enrollment":60},{"nctId":"NCT05008809","phase":"PHASE3","title":"Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)","status":"RECRUITING","sponsor":"Dominik Paul Modest","startDate":"2021-12-06","conditions":"Colorectal Cancer","enrollment":507},{"nctId":"NCT05417386","phase":"PHASE1","title":"FOLFIRINOX + NIS793 in Pancreatic Cancer","status":"TERMINATED","sponsor":"Colin D. Weekes, M.D., PhD","startDate":"2022-08-09","conditions":"Pancreas Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":4},{"nctId":"NCT05382442","phase":"PHASE2","title":"A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Akeso","startDate":"2022-06-27","conditions":"Metastatic Colorectal Cancer","enrollment":254},{"nctId":"NCT05990543","phase":"PHASE1, PHASE2","title":"Combination of Nelmastobart and Capecitabine Therapy in Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Korea University Anam Hospital","startDate":"2024-01-29","conditions":"Recurrent or Metastatic Colorectal Cancer","enrollment":59},{"nctId":"NCT06490536","phase":"PHASE3","title":"The Sagittarius Trial","status":"RECRUITING","sponsor":"IFOM ETS - The AIRC Institute of Molecular Oncology","startDate":"2024-10-22","conditions":"Colon Cancer Stage II, Colon Cancer Stage III","enrollment":700},{"nctId":"NCT04607421","phase":"PHASE3","title":"A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-21","conditions":"Neoplasms","enrollment":831},{"nctId":"NCT07104604","phase":"PHASE1","title":"Study on the Efficacy and Safety of Neoadjuvant Radiotherapy Combined With Toripalimab, Liposomal Irinotecan, and Capecitabine in the Treatment of pMMR Locally Advanced Rectal Adenocarcinoma With Low Rectal Involvement","status":"RECRUITING","sponsor":"Affiliated Cancer Hospital of Shantou University Medical College","startDate":"2025-08-01","conditions":"Rectal Cancer","enrollment":59},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT06963502","phase":"PHASE1","title":"A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2025-05-30","conditions":"Advanced Solid Tumors, Colorectal Cancer, Non-Small Cell Lung Cancer","enrollment":762},{"nctId":"NCT06622057","phase":"PHASE3","title":"D07001 Softgel-Capsules and Capecitabine Combination Therapy in Patients With Advanced Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"InnoPharmax Inc.","startDate":"2025-07-01","conditions":"Biliary Tract Cancer (BTC)","enrollment":195},{"nctId":"NCT04793932","phase":"PHASE3","title":"Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG (CASSANDRA TRIAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Associazione Italiana per lo Studio del Pancreas","startDate":"2020-11-03","conditions":"Pancreas Ductal Adenocarcinoma","enrollment":261},{"nctId":"NCT04920032","phase":"PHASE1","title":"Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas","status":"RECRUITING","sponsor":"University of California, Irvine","startDate":"2021-08-26","conditions":"Colon Adenocarcinoma, Colorectal Cancer","enrollment":22},{"nctId":"NCT05646511","phase":"PHASE3","title":"TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2022-11-21","conditions":"Locally Advanced Rectal Cancer","enrollment":608},{"nctId":"NCT05379790","phase":"PHASE1","title":"Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin","status":"COMPLETED","sponsor":"Erasmus Medical Center","startDate":"2022-05-25","conditions":"Gastric Cancer, Peritoneal Metastases","enrollment":20},{"nctId":"NCT06417476","phase":"PHASE2","title":"Short-course Radiotherapy or Long-course Chemoradiation Followed by MFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer","status":"RECRUITING","sponsor":"Pei-Rong Ding","startDate":"2022-12-12","conditions":"Rectal Neoplasms","enrollment":66},{"nctId":"NCT06578052","phase":"NA","title":"Irinotecan Liposome in Combination With Capecitabine","status":"RECRUITING","sponsor":"Junjie Hang","startDate":"2024-08-28","conditions":"Pancreatic Cancer","enrollment":20},{"nctId":"NCT02485834","phase":"PHASE2","title":"FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer","status":"TERMINATED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2015-11-12","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma, Gastric Cancer","enrollment":5},{"nctId":"NCT06139211","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study Of JS015 Combination Therapy in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2024-01-03","conditions":"Advanced Solid Tumor","enrollment":186},{"nctId":"NCT05314998","phase":"PHASE3","title":"Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature","status":"NOT_YET_RECRUITING","sponsor":"John Neoptolemos","startDate":"2025-01-15","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":394},{"nctId":"NCT06571461","phase":"PHASE3","title":"Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","startDate":"2024-09","conditions":"Pancreatic Cancer","enrollment":408},{"nctId":"NCT06463548","phase":"NA","title":"Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Yunpeng Liu","startDate":"2024-07-01","conditions":"Biliary Tract Carcinoma","enrollment":30},{"nctId":"NCT06430827","phase":"PHASE2","title":"Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Ba Yi","startDate":"2024-06-30","conditions":"Biliary Tract Carcinoma","enrollment":20},{"nctId":"NCT05238831","phase":"EARLY_PHASE1","title":"SMMART Adaptive Clinical Treatment (ACT) Trial","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2023-01-30","conditions":"Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma","enrollment":""},{"nctId":"NCT05737563","phase":"PHASE3","title":"PD-1 Antibody Combined With mXELIRI Versus mXELIRI in the Second-line Setting for ESCC","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-02-17","conditions":"Esophageal Squamous Cell Carcinoma Abdominal Stage 0","enrollment":380},{"nctId":"NCT06169202","phase":"","title":"A Study of Fruquintinib in Combination With Irinotecan and Capecitabine for the Second-line Treatment of Patients","status":"UNKNOWN","sponsor":"China Medical University, China","startDate":"2023-06-01","conditions":"Fruquintinib, Irinotecan, Capecitabine","enrollment":50},{"nctId":"NCT03485027","phase":"PHASE2","title":"Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2018-01-24","conditions":"Metastatic Colorectal Cancer, Chemotherapy Effect","enrollment":43},{"nctId":"NCT02024607","phase":"PHASE1, PHASE2","title":"A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2014-01","conditions":"Advanced Gastrointestinal Cancer","enrollment":495},{"nctId":"NCT06048146","phase":"NA","title":"A Prospective, Multicenter Randomized Controlled Study of the Application of Preoperative FOLFOXIRI Chemotherapy Combined With Lateral Lymph Node Dissection in Low- and Medium-lying Rectal Cancer With Lateral Lymph Node Metastasis","status":"ENROLLING_BY_INVITATION","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-10-01","conditions":"Lymph Node Metastasis, Cancer of Rectum and Anus, Oxaliplatin","enrollment":180},{"nctId":"NCT06099951","phase":"PHASE2","title":"Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer: Anti-PD-1 Antibody With FOLFOXIRI and Preoperative Radiation Therapy","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-11-01","conditions":"Colorectal Cancer","enrollment":53},{"nctId":"NCT05555901","phase":"PHASE2","title":"The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2023-06-18","conditions":"Metastatic Colorectal Cancer","enrollment":116},{"nctId":"NCT02324543","phase":"PHASE1, PHASE2","title":"Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-02","conditions":"Metastatic Pancreatic Adenocarcinoma","enrollment":47},{"nctId":"NCT02937116","phase":"PHASE1","title":"First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2016-10-19","conditions":"Cancer, Solid Tumor","enrollment":233},{"nctId":"NCT04389086","phase":"PHASE3","title":"Induction Chemotherapy for Locally Recurrent Rectal Cancer","status":"RECRUITING","sponsor":"Catharina Ziekenhuis Eindhoven","startDate":"2020-11-13","conditions":"Recurrent Rectal Cancer","enrollment":364},{"nctId":"NCT05235542","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors","status":"UNKNOWN","sponsor":"Akeso","startDate":"2022-07-12","conditions":"Advanced Malignant Tumors","enrollment":130},{"nctId":"NCT04089150","phase":"PHASE2","title":"MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease","status":"UNKNOWN","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2019-10-01","conditions":"Pancreatic Cancer","enrollment":120},{"nctId":"NCT02414009","phase":"PHASE2","title":"Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients","status":"COMPLETED","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2014-09","conditions":"Metastatic Colorectal Cancer","enrollment":82},{"nctId":"NCT01280643","phase":"NA","title":"Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Fox Chase Cancer Center","startDate":"2010-03","conditions":"Metastatic Colorectal Cancer","enrollment":3},{"nctId":"NCT03295084","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Oral Tablet of Irinotecan in Adult Patients With Solid Tumors","status":"COMPLETED","sponsor":"Dorte Nielsen","startDate":"2015-07-15","conditions":"Metastatic Colorectal Cancer","enrollment":39},{"nctId":"NCT01821729","phase":"PHASE2","title":"Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer","status":"UNKNOWN","sponsor":"Massachusetts General Hospital","startDate":"2013-07","conditions":"Pancreatic Cancer","enrollment":50},{"nctId":"NCT00081289","phase":"PHASE2","title":"Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2004-03","conditions":"Colorectal Cancer","enrollment":146},{"nctId":"NCT01588990","phase":"PHASE4","title":"A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-06-26","conditions":"Colorectal Neoplasms","enrollment":128},{"nctId":"NCT01996306","phase":"PHASE3","title":"A Phase III Study of 2nd-line XELIRI ± Bevacizumab vs. FOLFIRI ± Bevacizumab in mCRC","status":"COMPLETED","sponsor":"Epidemiological and Clinical Research Information Network","startDate":"2013-12-02","conditions":"Colorectal Neoplasms, Neoplasm Metastasis, Intestinal Neoplasms","enrollment":650},{"nctId":"NCT00215501","phase":"PHASE1","title":"Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2001-11","conditions":"Solid Tumor","enrollment":54},{"nctId":"NCT00276744","phase":"PHASE2","title":"Individualized Drug Treatment for Treating Patients With Pancreatic Cancer","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2005-10","conditions":"Pancreatic Cancer","enrollment":249},{"nctId":"NCT00003867","phase":"PHASE1","title":"Irinotecan and Capecitabine in Treating Patients With Solid Tumors","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"1999-03","conditions":"Cancer","enrollment":30},{"nctId":"NCT02004262","phase":"PHASE2","title":"Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting","status":"COMPLETED","sponsor":"Aduro Biotech, Inc.","startDate":"2014-02-05","conditions":"2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer","enrollment":303},{"nctId":"NCT00642603","phase":"PHASE2","title":"A Study of Xeloda (Capecitabine) in Combination With Avastin + Short Course Chemotherapy in Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2008-05","conditions":"Colorectal Cancer","enrollment":41},{"nctId":"NCT02720601","phase":"PHASE2","title":"Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers","status":"WITHDRAWN","sponsor":"New Mexico Cancer Research Alliance","startDate":"2015-11","conditions":"Biliary Tract Cancer","enrollment":""},{"nctId":"NCT00848783","phase":"PHASE2","title":"Irinotecan/Cisplatin, Potentially Curative Surgery With or Without Floxuridine, Followed by Capecitabine for Stomach and Gastro-esophageal Junction (GEJ) Cancers","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2008-05","conditions":"Gastric Cancer, Gastric Adenocarcinoma, Esophageal Cancer","enrollment":8},{"nctId":"NCT02271464","phase":"PHASE2","title":"Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Azienda Ospedaliero, Universitaria Pisana","startDate":"2012-03","conditions":"Metastatic Colorectal Cancer","enrollment":232},{"nctId":"NCT01765582","phase":"PHASE2","title":"Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2013-01-23","conditions":"Colorectal Neoplasms","enrollment":280},{"nctId":"NCT00433550","phase":"PHASE2","title":"Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2007-05","conditions":"Small Intestine Adenocarcinoma, Recurrent Small Intestine Cancer","enrollment":33},{"nctId":"NCT01333709","phase":"PHASE2","title":"Multicenter Phase 2 Trial: a Tailored Strategy for Locally Advanced Rectal Carcinoma","status":"COMPLETED","sponsor":"Institut du Cancer de Montpellier - Val d'Aurelle","startDate":"2011-05","conditions":"Locally Advanced Malignant Neoplasm, Rectal Carcinoma","enrollment":150},{"nctId":"NCT03245203","phase":"NA","title":"A Pilot Study of Neoadjuvant Chemotherapy Combined With Bevacizumab for Locally Advanced Rectal Cancer","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2017-08","conditions":"Rectal Cancer","enrollment":70},{"nctId":"NCT03146377","phase":"PHASE2","title":"Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2014-04","conditions":"Colorectal Cancer","enrollment":32},{"nctId":"NCT01558869","phase":"PHASE2","title":"Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2012-04","conditions":"Pancreatic Adenocarcinoma","enrollment":37},{"nctId":"NCT01374425","phase":"PHASE2","title":"Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-08","conditions":"Colorectal Cancer","enrollment":376},{"nctId":"NCT00022698","phase":"PHASE2","title":"Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2001-05","conditions":"Colorectal Cancer","enrollment":67},{"nctId":"NCT02688023","phase":"PHASE2","title":"Neoadjuvant Triplet Chemotherapy Regimen in Patients With Resectable Colorectal Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2014-03","conditions":"Colorectal Cancer","enrollment":50},{"nctId":"NCT00737438","phase":"PHASE2","title":"Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-08","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":22},{"nctId":"NCT00547547","phase":"PHASE1","title":"High-Selenium Brassica Juncea, Irinotecan, and Capecitabine in Treating Patients With Advanced Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2006-04","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":22},{"nctId":"NCT01454180","phase":"PHASE2","title":"Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets","status":"COMPLETED","sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","startDate":"2011-10","conditions":"Advanced Pancreatic Carcinoma","enrollment":31},{"nctId":"NCT01131078","phase":"PHASE2","title":"A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-06","conditions":"Colorectal Cancer","enrollment":306},{"nctId":"NCT00797485","phase":"PHASE3","title":"Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery","status":"UNKNOWN","sponsor":"Southern Italy Cooperative Oncology Group","startDate":"2008-07","conditions":"Colorectal Cancer","enrollment":672},{"nctId":"NCT00296062","phase":"PHASE1","title":"Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","startDate":"2006-03","conditions":"Colorectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":12},{"nctId":"NCT00532714","phase":"PHASE2","title":"Phase II Study of Irinotecan/Capecitabine in Patients With Antracycline/Taxane Pretreated MBC","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2006-08","conditions":"Breast Cancer Metastatic","enrollment":36},{"nctId":"NCT00006465","phase":"PHASE1","title":"Combination Chemotherapy in Treating Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2000-12","conditions":"Unspecified Adult Solid Tumor, Protocol Specific","enrollment":22},{"nctId":"NCT00101686","phase":"PHASE3","title":"Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-02","conditions":"Colorectal Neoplasms","enrollment":547},{"nctId":"NCT00312000","phase":"PHASE3","title":"Sequential Versus Combination Chemotherapy in Advanced Colorectal Carcinoma","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2003-01","conditions":"Advanced Colorectal Cancer","enrollment":820},{"nctId":"NCT00635323","phase":"PHASE2","title":"Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-11","conditions":"Carcinoma, Hepatocellular","enrollment":73}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Oral Capecitabine with Irinotecan","genericName":"Oral Capecitabine with Irinotecan","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Capecitabine is converted to 5-fluorouracil to inhibit thymidylate synthase and disrupt DNA synthesis, while irinotecan inhibits topoisomerase I to prevent DNA unwinding during replication, together producing synergistic cytotoxic effects against cancer cells. Used for Metastatic colorectal cancer, Metastatic gastric cancer, Metastatic breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}